Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2020-004437-20
    Sponsor's Protocol Code Number:JS001-027-III-HCC
    National Competent Authority:Italy - Italian Medicines Agency
    Clinical Trial Type:EEA CTA
    Trial Status:Trial now transitioned
    Date on which this record was first entered in the EudraCT database:2021-06-07
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedItaly - Italian Medicines Agency
    A.2EudraCT number2020-004437-20
    A.3Full title of the trial
    A prospective, randomized, placebo-controlled, double-blind, multicenter phase III registration clinical study to compare Toripalimab (JS001) combined with Lenvatinib versus placebo combined with Lenvatinib as the 1st-line therapy for advanced hepatocellular carcinoma (HCC)
    Studio clinico di registrazione prospettico, randomizzato, controllato con placebo, in doppio cieco, multicentrico di fase III volto a confrontare toripalimab (JS001) combinato con lenvatinib rispetto al placebo combinato con lenvatinib come terapia di prima linea per il carcinoma epatocellulare (HCC) in stadio avanzato
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A clinical study to compare Toripalimab (JS001) combined with Lenvatinib versus placebo combined with Lenvatinib as the 1st-line therapy for advanced hepatocellular carcinoma (HCC)
    Uno studio clinico per confrontare Toripalimab (JS001) combinato con Lenvatinib rispetto al placebo combinato con Lenvatinib come terapia di prima linea per il carcinoma epatocellulare avanzato (HCC)
    A.3.2Name or abbreviated title of the trial where available
    JS001-027-III-HCC
    JS001-027-III-HCC
    A.4.1Sponsor's protocol code numberJS001-027-III-HCC
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorShanghai Junshi Biosciences Co., Ltd.
    B.1.3.4CountryChina
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportShanghai Junshi Biosciences Co., Ltd
    B.4.2CountryChina
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationShanghai Junshi Biosciences Co., Ltd
    B.5.2Functional name of contact pointClinical Trial Information
    B.5.3 Address:
    B.5.3.1Street AddressNo.36 and 58, Haiqu Road, Floor 13, Building 2
    B.5.3.2Town/ cityShanghai
    B.5.3.3Post codeNot applicable
    B.5.3.4CountryChina
    B.5.6E-mailJS001_027_III_HCC@junshipharma.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameToripalimab
    D.3.2Product code [TAB001 and JS001]
    D.3.4Pharmaceutical form Solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.9.2Current sponsor codeJS001
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number40
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name LENVIMA
    D.2.1.1.2Name of the Marketing Authorisation holderEisai GmbH
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameLENVIMA
    D.3.2Product code [na]
    D.3.4Pharmaceutical form Capsule, hard
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNLENVATINIB
    D.3.9.1CAS number 417716-92-8
    D.3.9.2Current sponsor codena
    D.3.9.4EV Substance CodeSUB64419
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number4
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboSolution for infusion
    D.8.4Route of administration of the placeboIntravenous use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    advanced hepatocellular carcinoma (HCC)
    carcinoma epatocellulare avanzato (HCC)
    E.1.1.1Medical condition in easily understood language
    liver cancer
    cancro al fegato
    E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
    MedDRA Classification
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To observe, compare and evaluate the efficacy of Toripalimab combined with Lenvatinib (experimental group) versus placebo combined with Lenvatinib (control group) as the 1st-line therapy for patients with advanced hepatocellular carcinoma (HCC) through evaluation of overall survival (OS) and progression-free survival (PFS).
    Per osservare, confrontare e valutare l'efficacia di Toripalimab combinato con Lenvatinib (gruppo sperimentale) rispetto al placebo combinato con Lenvatinib (gruppo di controllo) come terapia di prima linea per pazienti con carcinoma epatocellulare avanzato (HCC) attraverso la valutazione della sopravvivenza globale (OS) sopravvivenza libera da progressione (PFS).
    E.2.2Secondary objectives of the trial
    - To evaluate and compare the efficacy of Toripalimab combined with Lenvatinib versus placebo combined with Lenvatinib as the 1st-line therapy for patients with advanced HCC through evaluation of objective response rate (ORR), duration of response (DOR), disease control rate (DCR) and time to progression (TTP) using the response evaluation criteria in solid tumors version 1.1 (RECIST v 1.1 criteria) and modified RECIST (mRECIST);
    - To evaluate the safety and tolerability of Toripalimab combined with Lenvatinib versus placebo combined with Lenvatinib as the 1st-line therapy for patients with advanced HCC;
    - To evaluate the pharmacokinetics (PK) profile of Toripalimab;
    - To evaluate the immunogenicity of Toripalimab.
    - Per valutare e confrontare l'efficacia di Toripalimab combinato con Lenvatinib rispetto al placebo combinato con Lenvatinib come terapia di prima linea per pazienti con HCC avanzato attraverso la valutazione del tasso di risposta obiettiva (ORR), della durata della risposta (DOR), del tasso di controllo della malattia (DCR ) e tempo alla progressione (TTP) utilizzando i criteri di valutazione della risposta nei tumori solidi versione 1.1 (criteri RECIST v 1.1) e RECIST modificato (mRECIST);
    - Valutare la sicurezza e la tollerabilità di Toripalimab combinato con Lenvatinib rispetto al placebo combinato con Lenvatinib come terapia di prima linea per pazienti con HCC avanzato;
    - Valutare il profilo farmacocinetico (PK) di toripalimab;
    - Valutare l'immunogenicità di Toripalimab.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Age of 18-75 full years (inclusive), male or female.
    2. Histopathologically or cytologically confirmed HCC or participants with liver cirrhosis meet the clinical diagnostic criteria for HCC of the American Association for the Study of Liver Diseases (AASLD).
    3. Stage B (intermediate stage) or C (advanced stage) HCC determined in accordance with Barcelona Clinic Liver Cancer staging system (BCLC stage), be unsuitable for surgery and/or local therapy, or have progression of disease after surgery and/or local therapy.
    4. No previous use of any systemic therapy for HCC (mainly including systemic chemotherapy, antiangiogenic drugs or other molecular targeted therapy, immunotherapy containing CTLA-4, PD-1/PD-L1 monoclonal antibody).
    5. Having = 1 measurable lesion in accordance with RECIST v1.1. Requirement: the selected target lesion has not been treated locally before, or is located in the area of previous local therapy and subsequently determined as PD through radiological examination and in accordance with RECIST v1.1.
    6. Child-Pugh class A or =7 class B, with no history of hepatic encephalopathy.
    7. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score 0-1.
    8. Expected survival =12 weeks.
    9. Main organ function meets the following requirements: no blood transfusion within 14 days prior to screening, no use of hematopoietic stimulating factor (including G-CSF, GM-CSF, EPO and TPO etc.) or human albumin preparation.
    - Absolute neutrophil count =1.5×109/L;
    - Platelet count = 75×109/L;
    - Haemoglobin = 90 g/L;
    - Serum albumin = 29 g/L;
    - Serum total bilirubin =2 × upper limit of normal (ULN);
    - Alanine aminotransferase (ALT), aspartate aminotransferase (AST) = 5×ULN;
    - Serum creatinine (Cr) =1.5×ULN or Cr clearance =50 mL/min (calculated by Cockcroft-Gault formula)
    - International normalized ratio (INR) =2 and prothrombin time (PT) =6 seconds exceeding ULN;
    - Urine protein < 2+ (If urine protein =2+, 24h urine protein quantification should be performed, the subjects with 24h urine protein quantification <1.0g can be enrolled).
    10. In case of HBsAg (+) and/or HBcAb (+), HBV DNA is required to be < 1000 IU/mL (if the lowest detectable value at the local center is higher than 1000IU/mL, enrollment can be determined based on the specific condition after discussed with sponsor), and it is required to continue original anti-HBV therapy in the full course, or start to use Entecavir or tenofovir in the full course after screening during the study.
    11. Female subjects at childbearing age must receive serum pregnancy test within 7 days before randomization, have negative result, and are willing to use reliable and effective contraceptive methods during the trial and within 60 days after last administration. Male subjects whose partners are women of childbearing potential must agree to use reliable and effective contraceptive methods during the trial and within 60 days after last administration.
    12. Being voluntary to participate in the study, sufficiently informed consent and sign the written informed consent form, with good compliance
    1. Età 18-75 anni (compresi), ambosessi.
    2. Soggetti con HCC istopatologicamente o citologicamente confermato o partecipanti con cirrosi epatica che soddisfano i criteri diagnostici clinici per l’HCC dell’American Association for the Study of Liver Diseases (AASLD [Associazione americana per lo studio delle malattie epatiche]).
    3. Partecipanti con HCC in stadio B (stadio intermedio) o C (stadio avanzato) determinato in base al sistema di stadiazione Barcelona Clinic Liver Cancer (stadio BCLC), non idonei all’intervento chirurgico e/o alla terapia locale oppure con progressione della malattia in seguito a intervento chirurgico e/o terapia locale.
    4. Nessun precedente utilizzo di terapia sistemica per l’HCC (principalmente composta da chemioterapia sistemica, farmaci antiangiogenici o altra terapia molecolare mirata, immunoterapia contenente CTLA-4, anticorpo monoclonale PD-1/PD-L1).
    5. Presenza di =1 lesione misurabile secondo i criteri RECIST v1.1. Requisito: la lesione target selezionata non deve essere stata precedentemente trattata a livello locale oppure deve trovarsi nell’area della precedente terapia locale e successivamente essere stata classificata come PD mediante esame radiologico, in conformità con i criteri RECIST v1.1.
    6. Classe A o classe B =7 di Child-Pugh, senza anamnesi di encefalopatia epatica.
    7. Punteggio dello stato di validità (PS) secondo l’Eastern Cooperative Oncology Group (ECOG) pari a 0 o 1.
    8. Sopravvivenza prevista =12 settimane.
    9. La funzione d’organo principale soddisfa i seguenti requisiti: nessuna trasfusione di sangue nei 14 giorni precedenti lo screening, nessun utilizzo di fattori di stimolazione ematopoietici (tra cui G-CSF, GM-CSF, EPO, TPO, ecc.) o di preparazioni a base di albumina umana.
    ¿ Conta assoluta dei neutrofili =1,5×10 9 /l.
    ¿ Conta piastrinica =75×10 9 /l.
    ¿ Emoglobina =90 g/l.
    ¿ Albumina sierica =29 g/l.
    ¿ Bilirubina sierica totale =2 volte il limite superiore della norma (ULN).
    ¿ Alanina aminotransferasi (ALT), aspartato aminotransferasi (AST), =5 volte l’ULN.
    ¿ Creatinina sierica (Cr) =1,5 volte l’ULN o clearance della Cr =50 ml/min (calcolate mediante la formula di Cockcroft-Gault).
    ¿ Rapporto normalizzato internazionale (INR) =2 e tempo di protrombina (PT) =6 secondi superiore all’ULN.
    ¿ Proteine urinarie <2+ (se il valore è =2+, dovrà essere eseguita la quantificazione delle proteine urinarie nelle 24 ore; i soggetti con quantificazione delle proteine urinarie nelle 24 ore <1,0 g possono essere arruolati).
    10. In caso di HBsAg (+) e/o HBcAb (+), il DNA dell’HBV deve essere <1000 UI/ml (se il valore rilevabile più basso presso il centro locale è superiore a 1000 UI/ml, l’arruolamento può essere determinato in base alla condizione specifica, previa consultazione dello sponsor); è necessario proseguire l’intero ciclo di terapia originale anti-HBV oppure deve essere avviata la somministrazione dell’intero ciclo di entecavir o tenofovir dopo lo screening durante lo studio.
    11. I soggetti di sesso femminile in età fertile devono sottoporsi a test di gravidanza sul siero nei 7 giorni precedenti la randomizzazione, devono fornire esito negativo e devono essere disposti a utilizzare metodi contraccettivi affidabili ed efficaci durante la sperimentazione e nei 60 giorni successivi all’ultima somministrazione. I soggetti di sesso maschile le cui compagne siano donne in età fertile devono accettare di utilizzare metodi contraccettivi affidabili ed efficaci durante la sperimentazione e nei 60 giorni successivi all’ultima somministrazione.
    12. Accettare di partecipare volontariamente allo studio, fornire un consenso informato sufficiente e firmare il modulo di consenso informato scritto, garantendo una buona conformità.
    E.4Principal exclusion criteria
    1. Known cholangiocellular carcinoma (ICC) or mixed hepatocellular carcinoma, sarcomatoid hepatocellular carcinoma and hepatic fibrolamellar carcinoma.
    2. Malignant tumor except HCC within 5 years: however, localized tumor cured in the study is excluded, including cervical carcinoma in situ, skin basal cell carcinoma and carcinoma in situ of prostate.
    3. Hepatic surgery and/or local therapy or treatment with investigational product for HCC within 4 weeks prior to randomization; palliative radiation therapy for bone metastatic lesion within 2 weeks prior to randomization; use of Chinese medicine preparations with anti-liver cancer effect within two weeks prior to randomization. Toxicity induced by previous therapy (except alopecia) not recovered to = grade 1 (NCI-CTCAE v5.0).
    4. Prior use of other anti-PD-1 antibody or other immunotherapy targeting PD-1/PD-L1.
    5. Uncontrolled pericardial effusion, uncontrolled pleural effusion or clinically obvious moderate or severe peritoneal effusion at screening, defined as reaching the following criteria: having clinical symptoms and pleural and peritoneal effusion detected in physical examination at screening; or puncture for drainage required for pleural and peritoneal effusion and/or intracavitary administration during screening.
    6. History of gastrointestinal hemorrhage within 6 months prior to randomization or clear tendency of gastrointestinal hemorrhage (including severe esophageal-gastric varices with hemorrhagic risk, locally active peptic ulcer, persistent fecal occult blood (+)).
    7. Having = grade 3 (NCI-CTCAE v5.0) gastrointestinal or non-gastrointestinal fistula at present.
    8. Cancer thrombus invasion in the main trunk of portal vein (Vp4) (more than 1/2 of the lumen), inferior vena cava cancer thrombus or cardiac involvement in accordance with CT/MRI.
    for the complete exclusion criteria please refer to the protocol and synopsis
    1. Noto carcinoma colangiocellulare (ICC) o carcinoma epatocellulare misto, carcinoma epatocellulare sarcomatoide e carcinoma fibrolamellare epatico.
    2. Tumore maligno, ad eccezione dell’HCC, entro 5 anni; sono tuttavia esclusi tumori localizzati curati nel corso dello studio, tra cui carcinoma cervicale in situ, carcinoma basocellulare cutaneo e carcinoma prostatico in situ.
    3. Chirurgia epatica e/o terapia locale o trattamento con prodotto sperimentale per l’HCC nelle 4 settimane precedenti la randomizzazione; radioterapia palliativa per la lesione metastatica ossea nelle 2 settimane precedenti la randomizzazione; uso di preparati della medicina cinese con effetto antitumorale a livello epatico nelle due settimane precedenti la randomizzazione. Mancato recupero dalla tossicità indotta da terapia precedente (tranne l’alopecia) ad un grado =1 (NCI-CTCAE v5.0).
    4. Precedente uso di altri anticorpi anti-PD-1 o altra immunoterapia mirata contro PD-1/PD-L1.
    5. Versamento pericardico non controllato, versamento pleurico non controllato o evidente versamento peritoneale clinicamente moderato o grave allo screening, definiti in base al raggiungimento dei seguenti criteri: presenza di sintomi clinici e versamento pleurico e peritoneale rilevati durante l’esame obiettivo allo screening; necessità di drenaggio del versamento pleurico e peritoneale e/o somministrazione intracavitaria durante lo screening.
    6. Anamnesi di emorragia gastrointestinale nei 6 mesi precedenti la randomizzazione o chiara tendenza dell’emorragia gastrointestinale (tra cui varici esofagee gravi con rischio emorragico, ulcera peptica localmente attiva, persistenza di sangue occulto nelle feci (+)).
    7. Presenza attuale di fistola gastrointestinale o non gastrointestinale di grado =3 (NCI-CTCAE v5.0).
    8. Invasione del trombo neoplastico nel tronco principale della vena porta (Vp4) (oltre 1/2 del lume), trombosi neoplastica della vena cava inferiore o coinvolgimento cardiaco secondo quanto evidenziato dalla TC/RMI.
    9. Gravi malattie cardiovascolari e cerebrovascolari:
    ¿ Scompenso cardiaco congestizio di classe II o superiore secondo la New York Heart Association (NYHA), angina pectoris instabile, infarto miocardico, insulto cerebrovascolare o aritmia scarsamente controllata nei 12 mesi precedenti la randomizzazione.
    ¿ Frazione di eiezione del ventricolo sinistro (FEVS) <50% secondo l’ecocolordoppler.
    ¿ Intervallo QT corretto (QTc) >480 ms (calcolato secondo il metodo Fridericia; in caso di QTc anomalo, è possibile calcolare la media mediante tre rilevazioni consecutive con un intervallo di 2 minuti).
    per i criteri completi si prega di fare riferimento al protocollo e alla sinossi sottomessi
    E.5 End points
    E.5.1Primary end point(s)
    Co-primary endpoints of progression-free survival (PFS) evaluated by blinded independent central review (BICR) using RECIST v1.1 and Overall survival (OS);
    Endpoint co-primari di sopravvivenza libera da progressione (PFS) valutati mediante revisione centrale indipendente in cieco (BICR) utilizzando RECIST v1.1 e sopravvivenza globale (OS);
    E.5.1.1Timepoint(s) of evaluation of this end point
    from C1D1 till end of survival follow-up
    da C1D1 fino alla fine del follow-up di sopravvivenza
    E.5.2Secondary end point(s)
    Efficacy:
    - ORR, DOR, DCR and TTP evaluated by BICR using RECIST v1.1;
    - ORR, DOR, DCR, TTP and PFS evaluated by investigators using RECIST v1.1;
    - ORR, DCR, DOR, TTP and PFS evaluated by BICR using modified RECIST (mRECIST) criteria;
    - Six-month and one-year PFS rate and one-year and two-year OS rate in both groups.

    Safety:
    - Incidence, severity and prognosis of adverse event (AE) and serious adverse event (SAE) judged in accordance with NCI-CTCAE v5.0; vital signs, ECG and abnormal laboratory examinations.

    PK and immunogenic parameters:
    - PK profile of Toripalimab.
    - Analysis of anti-drug antibody (ADA) during treatment.

    Other study endpoints:
    - ORR, DOR, DCR, TTP and PFS evaluated by investigators using iRECIST criteria;
    - Correlation between PD-L1 expression level in tumor tissue, proportion of strong positive expression of PD-L1, tumor mutation burden (TMB) and the efficacy of Toripalimab combined with Lenvatinib
    Efficacia:
    - ORR, DOR, DCR e TTP valutati da BICR utilizzando RECIST v1.1;
    - ORR, DOR, DCR, TTP e PFS valutati dagli investigatori utilizzando RECIST v1.1;
    - ORR, DCR, DOR, TTP e PFS valutati da BICR utilizzando criteri RECIST modificati (mRECIST);
    - Tasso di PFS a sei mesi e a un anno e tasso di OS a un anno e due anni in entrambi i gruppi.

    Sicurezza:
    - Incidenza, gravità e prognosi degli eventi avversi (AE) e degli eventi avversi gravi (SAE) valutati in conformità con NCI-CTCAE v5.0; segni vitali, ECG ed esami di laboratorio anormali.

    Parametri PK e immunogenici:
    - Profilo PK di Toripalimab.
    - Analisi degli anticorpi anti-farmaco (ADA) durante il trattamento.
    Altri endpoint dello studio:
    - ORR, DOR, DCR, TTP e PFS valutati dagli investigatori utilizzando criteri iRECIST;
    - Correlazione tra il livello di espressione di PD-L1 nel tessuto tumorale, percentuale di forte espressione positiva di PD-L1, carico di mutazione tumorale (TMB) e l'efficacia di Toripalimab combinato con Lenvatinib
    E.5.2.1Timepoint(s) of evaluation of this end point
    from C1D1 till end of survival follow-up
    da C1D1 fino alla fine del follow-up di sopravvivenza
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned6
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA12
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA Information not present in EudraCT
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    China
    Singapore
    Ukraine
    United States
    Italy
    Poland
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    The end time of the study is defined as the date of the last visit of the last patient (LPLV), or the date of collection of the last data required for statistical analysis, whichever comes earlier. The last data point needed in statistical analysis will be defined in statistical analysis plan in details.
    The sponsor has the right to decide to terminate this study at any time due to specific reasons (such as important safety concerns or force majeure).
    L'ora di fine dello studio è definita come la data dell'ultima visita dell'ultimo paziente (LPLV), o la data di raccolta degli ultimi dati richiesti per l'analisi statistica, se precedente. L'ultimo punto dati necessario nell'analisi statistica sarà definito in dettaglio nel piano di analisi statistica.
    Lo sponsor ha il diritto di decidere di interrompere questo studio in qualsiasi momento per motivi specifici (come importanti problemi di sicurezza o forza maggiore).
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years3
    E.8.9.1In the Member State concerned months36
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years4
    E.8.9.2In all countries concerned by the trial months0
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 400
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 119
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception Yes
    F.3.3.2Women of child-bearing potential using contraception No
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state18
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 30
    F.4.2.2In the whole clinical trial 519
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    After the consent is withdrawn, the subject will not be followed up for any reason. There will be no replacement for subjects who withdraw from the study.
    Dopo la revoca del consenso, il soggetto non sarà seguito per nessun motivo. Non ci sarà alcun sostituto per i soggetti che si ritirano dallo studio.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2021-05-03
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2021-02-24
    P. End of Trial
    P.End of Trial StatusTrial now transitioned
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 05 02:11:56 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA